Pfizer weight loss pill joins list of obesity drug flops

Sopa Images | Lightrocket | Getty ImagesPfizer's twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese...

Read more...

Amazon buys SpaceX rocket launches for Kuiper satellite internet project

A Falcon 9 rocket launches a Starlink mission on January 31, 2023 from Vandenberg Space Force Base in California.SpaceXAmazon bought three rocket launches from SpaceX for its Project Kuiper internet satellites, the tech giant announced on Friday.The move is a surprise from Amazon, given the company's Kuiper system aims...

Read more...

Stocks making the biggest moves midday: TSLA, DIS, BABA, ULTA

Check out the companies making headlines in midday trading. Tesla — Tesla shares slipped less than 1% as Wall Street assessed the company's long-anticipated Cybertruck following a delivery launch event Thursday in Texas. Disney — Disney shares were virtually flat after the entertainment giant reinstated its dividend at 30...

Read more...

Panera Bread IPO filing

A Panera Bread mango yuzu citrus charged lemonade is displayed at a Panera Bread restaurant in Novato, California, on Nov. 1, 2023.Justin Sullivan | Getty ImagesPanera Bread has confidentially filed to go public again, the Financial Times reported.The restaurant chain, known for its soups, sandwiches and bagels, has been...

Read more...

PFE, DIS, TSLA, BABA and more

Check out the companies making headlines in premarket trading. Pfizer -- Shares dropped 4.2% after the drugmaker said it would halt development of its twice-daily experimental weight-loss pill. Pfizer said patients in a mid-stage clinical study reported high rates of adverse side effects. It still plans to release trial...

Read more...

Pfizer to discontinue twice-daily version of weight loss pill

CFOTO | Future Publishing | Getty ImagesPfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side...

Read more...